Breaking News Instant updates and real-time market news.

VRDN

Viridian Therapeutics

$19.99 /

+0.55 (+2.83%)

15:51
10/23/22
10/23
15:51
10/23/22
15:51

Viridian Therapeutics presents data from ongoing VRDN-001 Phase 1/2 trial

Viridian Therapeutics presented proof-of-concept data from the 10 mg/kg cohort in its ongoing Phase 1/2 clinical trial of VRDN-001, an anti-IGF-1R antibody, in patients with active thyroid eye disease. These data, as well as new in vitro data further characterizing and differentiating the pharmacological profile of VRDN-001, were included as part of three late-breaking poster presentations at the American Thyroid Association 91st Annual Meeting. The abstract describing new in vitro data on the distinct anti-IGF-1R profile of VRDN-001 was also selected as an oral highlighted late breaking presentation. ATA Poster #535: "VRDN-001, a Full Antagonist Antibody to the Insulin-Like Growth Factor Receptor-1 (IGF-1R) for Thyroid Eye Disease (TED): Phase 1/2 Proof of Concept in Patients with TED" presents proof-of-concept data from the first cohort of patients with active TED treated in the ongoing Phase 1/2 clinical trial. In this cohort, a total of 8 patients were randomized to receive two infusions of 10 mg/kg dose of VRDN-001 or placebo intravenously; 6 patients received VRDN-001 and 2 patients received placebo. In patients receiving VRDN-001, proptosis response was achieved by 83% of patients, with a mean reduction of 2.4 mm from baseline. Clinical Activity Score of 0 or 1 was achieved by 83% of patients, with a mean reduction of 4.3 points from baseline. Complete resolution of diplopia was achieved by 75% of patients who presented with diplopia at baseline. VRDN-001 demonstrated a favorable safety and tolerability profile with no reported SAEs, no hyperglycemia, and no infusion reactions. ATA Poster #568: "VRDN-001, A Potent and Selective Insulin-Like Growth Factor-1 Receptor (IGF-1R) Antagonist Antibody for Thyroid Eye Disease (TED): Phase 1 Safety and Pharmacodynamic Results in Healthy Volunteers" presents full safety and pharmacodynamic data from the completed healthy volunteer portion of the ongoing Phase 1/2 trial of VRDN-001. A total of 13 subjects were randomized to receive two infusions of either 3, 10, or 20 mg/kg dose of VRDN-001 or placebo. Twelve subjects completed the trial; one of the subjects in the 20 mg/kg group withdrew for personal reasons after the first infusion and was followed through Day 35. Plasma levels of IGF-1, a biomarker for IGF-1R antagonism, increased five- to seven-fold above baseline indicating maximal target engagement at all doses. All doses studied were generally safe and well tolerated, with no cases of hearing impairment or treatment related hyperglycemia and no infusion reactions. ATA Poster #132: "VRDN-001, a Full Antagonist Antibody to the Insulin-Like Growth Factor-1 Receptor (IGF-1R) in Development for Thyroid Eye Disease (TED), Binds to a Distinct Epitope from Teprotumumab" presents preclinical data from in vitro studies of VRDN-001.The data show that VRDN-001 binds the same region of the IGF-1R as teprotumumab but engages a distinct epitope. This difference in binding translated to differences in functional effects: unlike the anti-IGF-1R antibody teprotumumab, which incompletely antagonized IGF-1R function, VRDN-001 fully antagonized ligand binding, receptor autophosphorylation, and downstream signaling. These pharmacological differences may provide a mechanistic basis for the initial data reported from the ongoing VRDN-001 Phase 1/2 study, including the pharmacodynamic responses in the healthy volunteer cohort presented in Poster #568 and favorable clinical responses seen in TED patients as presented in Poster #535. The company remains on track to present additional updates from the VRDN-001 Phase 1/2 study this quarter. These updates will include top-line data for the 20 mg/kg cohort of the ongoing Phase 1/2 trial of VRDN-001 in TED, followed later this quarter by top-line data from the currently enrolling 3 mg/kg cohort. This ongoing trial is evaluating two infusions of VRDN-001, three weeks apart, with efficacy measured six weeks after the first dose. Each dose is evaluated in a cohort of eight patients, randomized so that six patients receive VRDN-001 and two patients receive placebo. The first cohort evaluated a dose of 10 mg/kg, with initial clinical data reported on August 15, 2022. The Company expects to initiate the pivotal program for VRDN-001 by the end of 2022. This quarter the company also will report final pharmacokinetic and pharmacodynamic data from Viridian's first-in-human trial of VRDN-002, a half-life extended IGF-1R antibody, which build upon the recently presented interim results. The Company expects data from a proof-of-concept trial of subcutaneously administered VRDN-002 in the second half of 2023.

  • 17

    Aug

OTHER BREAKING NEWS FROM THE FLY

Conference/Events
Steven Madden management to meet with Loop Capital » 07:51
02/03/23
02/03
07:51
02/03/23
07:51
SHOO

Steven Madden

$37.49 /

+1.135 (+3.12%)

Meeting to be held in…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
SHOO Steven Madden
$37.49 /

+1.135 (+3.12%)

11/01/22 Wedbush
Steven Madden downgraded to Neutral from Outperform at Wedbush
10/21/22 Citi
Steven Madden price target lowered to $31 from $36 at Citi
10/21/22 Citi
Citi opens 'positive catalyst watch' on Steven Madden
09/28/22 CL King
Steven Madden upgraded to Buy from Neutral at CL King
SHOO Steven Madden
$37.49 /

+1.135 (+3.12%)

SHOO Steven Madden
$37.49 /

+1.135 (+3.12%)

Downgrade
Synaptics downgraded to Perform from Outperform at Oppenheimer » 07:50
02/03/23
02/03
07:50
02/03/23
07:50
SYNA

Synaptics

$139.79 /

+7.25 (+5.47%)

Oppenheimer analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
SYNA Synaptics
$139.79 /

+7.25 (+5.47%)

SYNA Synaptics
$139.79 /

+7.25 (+5.47%)

07:32 Today Cowen
Synaptics price target raised to $150 from $100 at Cowen
07:20 Today BMO Capital
Synaptics price target raised to $135 from $90 at BMO Capital
11/04/22 BMO Capital
Synaptics price target lowered to $90 from $110 at BMO Capital
11/04/22 Craig-Hallum
Synaptics price target lowered to $120 from $180 at Craig-Hallum
SYNA Synaptics
$139.79 /

+7.25 (+5.47%)

Upgrade
Boyd Gaming upgraded to Buy from Hold at CBRE » 07:50
02/03/23
02/03
07:50
02/03/23
07:50
BYD

Boyd Gaming

/

+

CBRE analyst John DeCree…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
BYD Boyd Gaming
/

+

BYD Boyd Gaming
/

+

01/18/23 Roth Capital
Boyd Gaming initiated with a Buy at Roth Capital
01/17/23 Credit Suisse
Boyd Gaming initiated with an Outperform at Credit Suisse
01/11/23 Truist
Boyd Gaming price target raised to $80 from $79 at Truist
12/12/22 JMP Securities
Boyd Gaming downgraded to Market Perform from Outperform at JMP Securities
BYD Boyd Gaming
/

+

BYD Boyd Gaming
/

+

Recommendations
MicroStrategy price target raised to $400 from $372 at Canaccord » 07:50
02/03/23
02/03
07:50
02/03/23
07:50
MSTR

MicroStrategy

$291.68 /

+22.9 (+8.52%)

Canaccord analyst Joseph…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
MSTR MicroStrategy
$291.68 /

+22.9 (+8.52%)

MSTR MicroStrategy
$291.68 /

+22.9 (+8.52%)

12/29/22 Jefferies
MicroStrategy price target lowered to $110 from $140 at Jefferies
11/09/22 Jefferies
MicroStrategy price target lowered to $140 from $175 at Jefferies
10/31/22 Jefferies
MicroStrategy price target lowered to $175 from $180 at Jefferies
08/03/22 Canaccord
MicroStrategy price target lowered to $372 from $453 at Canaccord
MSTR MicroStrategy
$291.68 /

+22.9 (+8.52%)

MSTR MicroStrategy
$291.68 /

+22.9 (+8.52%)

MSTR MicroStrategy
$291.68 /

+22.9 (+8.52%)

MSTR MicroStrategy
$291.68 /

+22.9 (+8.52%)

Recommendations
Ezcorp price target raised to $15 from $14 at Canaccord » 07:49
02/03/23
02/03
07:49
02/03/23
07:49
EZPW

Ezcorp

$9.03 /

+0.015 (+0.17%)

Canaccord analyst Brian…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
EZPW Ezcorp
$9.03 /

+0.015 (+0.17%)

EZPW Ezcorp
$9.03 /

+0.015 (+0.17%)

01/04/23 Canaccord
Canaccord starts Ezcorp with a Buy, says discount 'undeserved'
01/04/23 Canaccord
Ezcorp initiated with a Buy at Canaccord
04/05/22 Jefferies
Ezcorp upgraded to Buy from Hold at Jefferies
EZPW Ezcorp
$9.03 /

+0.015 (+0.17%)

EZPW Ezcorp
$9.03 /

+0.015 (+0.17%)

Hot Stocks
IES Holdings sees higher cash tax rate for 2023 vs. 2022 » 07:48
02/03/23
02/03
07:48
02/03/23
07:48
IESC

IES Holdings

$40.58 /

+0.635 (+1.59%)

"During the first…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
IESC IES Holdings
$40.58 /

+0.635 (+1.59%)

IESC IES Holdings
$40.58 /

+0.635 (+1.59%)

Downgrade
Stanley Black & Decker downgraded to Neutral from Buy at Longbow » 07:48
02/03/23
02/03
07:48
02/03/23
07:48
SWK

Stanley Black & Decker

$95.87 /

+4.935 (+5.43%)

Longbow analyst David…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
SWK Stanley Black & Decker
$95.87 /

+4.935 (+5.43%)

SWK Stanley Black & Decker
$95.87 /

+4.935 (+5.43%)

07:43 Today Longbow
Stanley Black & Decker downgraded to Neutral from Buy at Longbow
01/13/23 Mizuho
Stanley Black & Decker price target raised to $90 from $80 at Mizuho
10/31/22 Citi
Stanley Black & Decker price target lowered to $69 from $90 at Citi
10/28/22 Mizuho
Stanley Black & Decker price target lowered to $80 from $85 at Mizuho
SWK Stanley Black & Decker
$95.87 /

+4.935 (+5.43%)

SWK Stanley Black & Decker
$95.87 /

+4.935 (+5.43%)

SWK Stanley Black & Decker
$95.87 /

+4.935 (+5.43%)

Recommendations
Bill.com price target lowered to $175 from $250 at Canaccord » 07:48
02/03/23
02/03
07:48
02/03/23
07:48
BILL

Bill.com

/

+

Canaccord analyst Joseph…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
BILL Bill.com
/

+

BILL Bill.com
/

+

07:21 Today JPMorgan
Bill.com price target lowered to $135 from $161 at JPMorgan
07:20 Today Wells Fargo
Bill.com price target lowered to $138 from $180 at Wells Fargo
06:47 Today Mizuho
Bill.com price target lowered to $100 from $105 at Mizuho
06:46 Today BMO Capital
Bill.com downgraded to Market Perform at BMO following 'tough' Q2
BILL Bill.com
/

+

BILL Bill.com
/

+

BILL Bill.com
/

+

Recommendations
Skechers price target raised to $69 from $63 at UBS » 07:48
02/03/23
02/03
07:48
02/03/23
07:48
SKX

Skechers

/

+

UBS analyst Jay Sole…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
SKX Skechers
/

+

SKX Skechers
/

+

07:40 Today Cowen
Skechers price target lowered to $62 from $65 at Cowen
01/23/23 Cowen
Skechers upgraded to Outperform at Cowen on momentum and margin recovery
01/23/23 Deutsche Bank
Skechers price target raised to $54 from $43 at Deutsche Bank
01/23/23 Cowen
Skechers upgraded to Outperform from Market Perform at Cowen
SKX Skechers
/

+

SKX Skechers
/

+

SKX Skechers
/

+

Recommendations
Kulicke & Soffa price target raised to $55 from $45 at B. Riley » 07:48
02/03/23
02/03
07:48
02/03/23
07:48
KLIC

Kulicke & Soffa

$58.28 /

+4.7 (+8.77%)

B. Riley analyst Craig…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
KLIC Kulicke & Soffa
$58.28 /

+4.7 (+8.77%)

KLIC Kulicke & Soffa
$58.28 /

+4.7 (+8.77%)

11/18/22 DA Davidson
Kulicke & Soffa price target raised to $60 from $55 at DA Davidson
10/17/22 DA Davidson
Kulicke & Soffa price target lowered to $55 from $70 at DA Davidson
10/04/22 B. Riley
Kulicke & Soffa price target lowered to $45 from $50 at B. Riley
06/15/22 B. Riley
Kulicke & Soffa price target lowered to $50 from $59 at B. Riley
KLIC Kulicke & Soffa
$58.28 /

+4.7 (+8.77%)

KLIC Kulicke & Soffa
$58.28 /

+4.7 (+8.77%)

Hot Stocks
IES Holdings 'optimistic' about long-term fundamentals in 'key markets' » 07:48
02/03/23
02/03
07:48
02/03/23
07:48
IESC

IES Holdings

$40.58 /

+0.635 (+1.59%)

CEO Jeff Gendell…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
IESC IES Holdings
$40.58 /

+0.635 (+1.59%)

IESC IES Holdings
$40.58 /

+0.635 (+1.59%)

Hot Stocks
Littelfuse acquires Western Automation Research and Development » 07:48
02/03/23
02/03
07:48
02/03/23
07:48
LFUS

Littelfuse

$271.67 /

+11.01 (+4.22%)

Littelfuse announced it…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
LFUS Littelfuse
$271.67 /

+11.01 (+4.22%)

06:54 Today Baird
Littelfuse price target raised to $270 from $258 at Baird
11/22/22 Jefferies
Littelfuse price target raised to $295 from $254 at Jefferies
11/03/22 Cowen
Littelfuse downgraded to Market Perform from Outperform at Cowen
11/03/22 Cowen
Littelfuse downgraded to Market Perform from Outperform at Cowen
LFUS Littelfuse
$271.67 /

+11.01 (+4.22%)

Recommendations
Viavi price target lowered to $13.50 from $14.50 at B. Riley » 07:47
02/03/23
02/03
07:47
02/03/23
07:47
VIAV

Viavi

$11.50 /

+0.055 (+0.48%)

B. Riley analyst Dave…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
VIAV Viavi
$11.50 /

+0.055 (+0.48%)

VIAV Viavi
$11.50 /

+0.055 (+0.48%)

12/20/22 JPMorgan
Viavi price target lowered to $11 from $13 at JPMorgan
12/01/22 Stifel
Viavi initiated with a Hold at Stifel
11/18/22 Lake Street
Clearfield price target raised to $135 from $122 at Lake Street
11/04/22 B. Riley
Viavi downgraded to Neutral from Buy at B. Riley
VIAV Viavi
$11.50 /

+0.055 (+0.48%)

VIAV Viavi
$11.50 /

+0.055 (+0.48%)

Recommendations
Rogers Communications price target raised to C$69 from C$68 at Canaccord » 07:47
02/03/23
02/03
07:47
02/03/23
07:47
RCI

Rogers Communications

/

+

Canaccord analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
RCI Rogers Communications
/

+

RCI Rogers Communications
/

+

01/12/23 CIBC
Rogers Communications price target raised to C$72 from C$69 at CIBC
01/12/23 National Bank
Rogers Communications price target raised to C$78 from C$75 at National Bank
01/10/23 Canaccord
Shaw Communications downgraded to Hold from Buy at Canaccord
01/03/23 National Bank
Shaw Communications cut to Sector Perform from Outperform at National Bank
RCI Rogers Communications
/

+

RCI Rogers Communications
/

+

RCI Rogers Communications
/

+

Recommendations
Ford price target lowered to $19 from $21 at Benchmark » 07:47
02/03/23
02/03
07:47
02/03/23
07:47
F

Ford

/

+

Benchmark analyst Michael…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
F Ford
/

+

F Ford
/

+

06:37 Today Deutsche Bank
Deutsche downgrades Ford to Sell on 'meaningful' earnings risk
06:04 Today Deutsche Bank
Ford downgraded to Sell from Hold at Deutsche Bank
01/25/23 JPMorgan
Ford price target lowered to $15 from $16 at JPMorgan
01/11/23 Goldman Sachs
Goldman continues to prefer Tesla and GM among automakers
F Ford
/

+

F Ford
/

+

F Ford
/

+

F Ford
/

+

Earnings
IES Holdings reports Q1 adjusted EPS 82c vs. 83c last year » 07:46
02/03/23
02/03
07:46
02/03/23
07:46
IESC

IES Holdings

$40.58 /

+0.635 (+1.59%)

Reports Q1 revenue $575M…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
IESC IES Holdings
$40.58 /

+0.635 (+1.59%)

IESC IES Holdings
$40.58 /

+0.635 (+1.59%)

Recommendations
Microchip price target raised to $106 from $86 at B. Riley » 07:46
02/03/23
02/03
07:46
02/03/23
07:46
MCHP

Microchip

/

+

B. Riley analyst Craig…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
MCHP Microchip
/

+

MCHP Microchip
/

+

06:58 Today Citi
Microchip price target raised to $85 from $74 at Citi
06:57 Today Raymond James
Microchip price target raised to $105 from $90 at Raymond James
06:41 Today Mizuho
Microchip price target raised to $79 from $72 at Mizuho
06:11 Today Piper Sandler
Microchip price target raised to $100 from $80 at Piper Sandler
MCHP Microchip
/

+

MCHP Microchip
/

+

MCHP Microchip
/

+

MCHP Microchip
/

+

Recommendations
Ferrari price target raised to $330 from $274 at UBS » 07:46
02/03/23
02/03
07:46
02/03/23
07:46
RACE

Ferrari

$265.45 /

+12.315 (+4.87%)

UBS analyst Susy Tibaldi…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
RACE Ferrari
$265.45 /

+12.315 (+4.87%)

RACE Ferrari
$265.45 /

+12.315 (+4.87%)

07:33 Today Credit Suisse
Ferrari price target raised to $310 from $290 at Credit Suisse
01/09/23 Citi
Ferrari upgraded to Neutral from Sell at Citi
12/09/22 RBC Capital
Ferrari price target raised to EUR 265 from EUR 261 at RBC Capital
11/29/22 Bernstein
Tesla risk/reward 'more balanced' after 48% drop, says Bernstein
RACE Ferrari
$265.45 /

+12.315 (+4.87%)

RACE Ferrari
$265.45 /

+12.315 (+4.87%)

Recommendations
Iteris price target raised to $4.50 from $3.50 at B. Riley » 07:46
02/03/23
02/03
07:46
02/03/23
07:46
ITI

Iteris

$3.95 /

+0.21 (+5.61%)

B. Riley analyst Jeff Van…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
ITI Iteris
$3.95 /

+0.21 (+5.61%)

ITI Iteris
$3.95 /

+0.21 (+5.61%)

11/21/22 EF Hutton
Iteris initiated with a Buy at EF Hutton
06/02/22 B. Riley
Iteris price target lowered to $5 from $6 at B. Riley
02/04/22 Craig-Hallum
Iteris downgraded to Hold from Buy at Craig-Hallum
02/04/22 B. Riley
Iteris price target lowered to $6 from $8 at B. Riley
ITI Iteris
$3.95 /

+0.21 (+5.61%)

Recommendations
GeoPark price target lowered to $18.50 from $19 at Canaccord » 07:45
02/03/23
02/03
07:45
02/03/23
07:45
GPRK

GeoPark

$14.30 /

-0.64 (-4.28%)

Canaccord analyst Roman…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
GPRK GeoPark
$14.30 /

-0.64 (-4.28%)

GPRK GeoPark
$14.30 /

-0.64 (-4.28%)

11/10/22 Bradesco BBI
GeoPark downgraded to Neutral from Outperform at Bradesco BBI
08/12/22 Canaccord
GeoPark price target lowered to $22 from $24 at Canaccord
GPRK GeoPark
$14.30 /

-0.64 (-4.28%)

Recommendations
Eos Energy price target lowered to $3 from $4 at B. Riley » 07:45
02/03/23
02/03
07:45
02/03/23
07:45
EOSE

Eos Energy

$1.33 /

-0.135 (-9.22%)

B. Riley analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
EOSE Eos Energy
$1.33 /

-0.135 (-9.22%)

EOSE Eos Energy
$1.33 /

-0.135 (-9.22%)

12/02/22 Stifel
Eos Energy initiated with a Buy at Stifel
11/09/22 B. Riley
Eos Energy price target lowered to $4 from $6 at B. Riley
10/27/22 EF Hutton
Eos Energy initiated with a Buy at EF Hutton
08/03/22 B. Riley
Eos Energy price target lowered to $6 from $7 at B. Riley
EOSE Eos Energy
$1.33 /

-0.135 (-9.22%)

EOSE Eos Energy
$1.33 /

-0.135 (-9.22%)

EOSE Eos Energy
$1.33 /

-0.135 (-9.22%)

Recommendations
Vista Outdoor price target lowered to $41 from $45 at B. Riley » 07:43
02/03/23
02/03
07:43
02/03/23
07:43
VSTO

Vista Outdoor

$29.08 /

-0.81 (-2.71%)

B. Riley analyst Eric…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
VSTO Vista Outdoor
$29.08 /

-0.81 (-2.71%)

VSTO Vista Outdoor
$29.08 /

-0.81 (-2.71%)

11/07/22 Lake Street
Vista Outdoor price target lowered to $45 from $53 at Lake Street
10/25/22 MKM Partners
Vista Outdoor price target lowered to $51 from $54 at MKM Partners
09/20/22 Jefferies
Vista Outdoor initiated with a Hold at Jefferies
09/19/22 B. Riley
Vista Outdoor well positioned for share gains, says B. Riley
VSTO Vista Outdoor
$29.08 /

-0.81 (-2.71%)

VSTO Vista Outdoor
$29.08 /

-0.81 (-2.71%)

VSTO Vista Outdoor
$29.08 /

-0.81 (-2.71%)

Downgrade
Stanley Black & Decker downgraded to Neutral from Buy at Longbow » 07:43
02/03/23
02/03
07:43
02/03/23
07:43
SWK

Stanley Black & Decker

/

+

Longbow analyst David…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
SWK Stanley Black & Decker
/

+

SWK Stanley Black & Decker
/

+

01/13/23 Mizuho
Stanley Black & Decker price target raised to $90 from $80 at Mizuho
10/31/22 Citi
Stanley Black & Decker price target lowered to $69 from $90 at Citi
10/28/22 Mizuho
Stanley Black & Decker price target lowered to $80 from $85 at Mizuho
10/28/22 Baird
Stanley Black & Decker downgraded to Neutral at Baird amid macro risks
SWK Stanley Black & Decker
/

+

SWK Stanley Black & Decker
/

+

SWK Stanley Black & Decker
/

+

Recommendations
Canada Goose price target lowered to $22 from $26 at Cowen » 07:43
02/03/23
02/03
07:43
02/03/23
07:43
GOOS

Canada Goose

$18.80 /

-5.845 (-23.72%)

Cowen analyst Oliver Chen…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
GOOS Canada Goose
$18.80 /

-5.845 (-23.72%)

GOOS Canada Goose
$18.80 /

-5.845 (-23.72%)

01/27/23 Cowen
Canada Goose price target raised to $26 from $24 at Cowen
01/26/23 OTR Global
Canada Goose downgraded to Negative from Mixed view at OTR Global
01/24/23 Baird
Canada Goose downgraded to Neutral from Outperform at Baird
11/03/22 Baird
Canada Goose price target lowered to $25 from $30 at Baird
GOOS Canada Goose
$18.80 /

-5.845 (-23.72%)

GOOS Canada Goose
$18.80 /

-5.845 (-23.72%)

GOOS Canada Goose
$18.80 /

-5.845 (-23.72%)

Recommendations
Starbucks price target raised to $116 from $112 at Cowen » 07:42
02/03/23
02/03
07:42
02/03/23
07:42
SBUX

Starbucks

/

+

Cowen analyst Andrew…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
SBUX Starbucks
/

+

SBUX Starbucks
/

+

07:39 Today Credit Suisse
Starbucks price target raised to $122 from $116 at Credit Suisse
06:50 Today Barclays
Starbucks price target raised to $123 from $121 at Barclays
01/30/23 Stifel
Starbucks price target raised to $117 from $93 at Stifel
01/30/23 Baird
Starbucks price target raised to $110 from $94 at Baird
SBUX Starbucks
/

+

SBUX Starbucks
/

+

SBUX Starbucks
/

+

SBUX Starbucks
/

+

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.